S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
S&P 500   4,283.74 (+0.23%)
DOW   33,999.04 (+0.06%)
QQQ   329.58 (+0.33%)
AAPL   174.09 (-0.26%)
MSFT   290.09 (-0.42%)
META   174.55 (-0.17%)
GOOGL   120.10 (+0.46%)
AMZN   142.34 (+0.17%)
TSLA   908.45 (-0.39%)
NVDA   187.80 (+2.43%)
NIO   19.87 (-1.05%)
BABA   90.71 (+1.05%)
AMD   100.49 (+2.26%)
MU   63.08 (+2.37%)
T   18.40 (-0.11%)
CGC   3.80 (-6.40%)
F   16.14 (+0.69%)
GE   79.23 (-0.86%)
DIS   122.55 (-0.21%)
AMC   19.06 (-10.77%)
PYPL   99.85 (+0.43%)
PFE   48.59 (-1.38%)
NFLX   244.83 (+1.53%)
NASDAQ:MGTX

MeiraGTx - MGTX Stock Forecast, Price & News

$9.91
+0.12 (+1.23%)
(As of 08/18/2022 03:59 PM ET)
Add
Compare
Today's Range
$9.53
▼
$10.07
50-Day Range
$6.80
▼
$11.25
52-Week Range
$6.59
▼
$24.89
Volume
1,310 shs
Average Volume
137,904 shs
Market Capitalization
$443.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.25

MeiraGTx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
208.7% Upside
$30.25 Price Target
Short Interest
Bearish
6.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.85mentions of MeiraGTx in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$47,440 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.36) to ($2.06) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.45 out of 5 stars

Medical Sector

228th out of 1,122 stocks

Biological Products, Except Diagnostic Industry

37th out of 178 stocks

See Top Rated MarketRank™ Stocks Here
MGTX stock logo

About MeiraGTx (NASDAQ:MGTX) Stock

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

Wall Street Analyst Weigh In

A number of analysts have commented on MGTX shares. Chardan Capital increased their price objective on shares of MeiraGTx from $46.00 to $47.00 and gave the company a "buy" rating in a report on Friday, August 12th. Barclays cut their price target on shares of MeiraGTx from $32.00 to $18.00 in a report on Friday, May 13th. Finally, Piper Sandler cut their price target on shares of MeiraGTx from $40.00 to $30.00 in a report on Thursday, May 12th.

MeiraGTx Stock Down 6.9 %

Shares of NASDAQ:MGTX opened at $9.79 on Thursday. The company has a 50 day simple moving average of $8.38 and a 200-day simple moving average of $10.89. The company has a market capitalization of $437.71 million, a P/E ratio of -4.31 and a beta of 1.76. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.55 and a quick ratio of 1.55. MeiraGTx has a 1 year low of $6.59 and a 1 year high of $24.89.

Insider Transactions at MeiraGTx

In other news, insider Robert K. Zeldin purchased 5,000 shares of the business's stock in a transaction dated Friday, June 3rd. The stock was acquired at an average price of $7.90 per share, for a total transaction of $39,500.00. Following the acquisition, the insider now directly owns 5,000 shares of the company's stock, valued at $39,500. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 13.30% of the company's stock.

Receive MGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter.

MGTX Stock News Headlines

August 11, 2022 | globenewswire.com
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results - GlobeNewswire
August 11, 2022 | finance.yahoo.com
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results - Yahoo Finance
August 11, 2022 | finance.yahoo.com
MeiraGTx Reports Second Quarter 2022 Financial and Operational Results
August 9, 2022 | nasdaq.com
Epizyme (EPZM) Reports Q2 Loss, Tops Revenue Estimates - Nasdaq
August 5, 2022 | nasdaq.com
Vanda Pharmaceuticals (VNDA) Q2 Earnings and Revenues Miss Estimates - Nasdaq
August 4, 2022 | streetinsider.com
Form 8-K MeiraGTx Holdings plc For: Aug 02 - StreetInsider.com
August 3, 2022 | seekingalpha.com
MGTX stock gains on $100M debt agreement (NASDAQ:MGTX) - Seeking Alpha
August 3, 2022 | globenewswire.com
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities - GlobeNewswire
August 3, 2022 | finance.yahoo.com
MeiraGTx Announces Financing Agreement with Perceptive Advisors for Up to $100 Million Secured by Manufacturing Facilities
July 15, 2022 | fortune.com
A bank CFO that excels at storytelling—through numbers - Fortune
July 11, 2022 | businesswire.com
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer - Business Wire
June 28, 2022 | finance.yahoo.com
MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial
June 28, 2022 | streetinsider.com
MeiraGTx Holdings plc (MGTX) Reports Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision - StreetInsider.com
June 28, 2022 | globenewswire.com
MeiraGTx Announces Positive Top-Line Data from the MGT009 Phase 1/2 Clinical Study Demonstrating Safety and Improvement in Multiple Domains of Vision in X-Linked Retinitis Pigmentosa Patients treated with Botaretigene Sparoparvovec (AAV-RPGR) co - GlobeNewswire
June 16, 2022 | finance.yahoo.com
Further weakness as MeiraGTx Holdings (NASDAQ:MGTX) drops 13% this week, taking three-year losses to 67%
May 13, 2022 | benzinga.com
Barclays Maintains Overweight on MeiraGTx Hldgs, Lowers Price Target to $18 - Benzinga - Benzinga
May 13, 2022 | benzinga.com
MeiraGTx Hldgs: Q1 Earnings Insights - Benzinga - Benzinga
May 12, 2022 | finance.yahoo.com
MeiraGTx Reports First Quarter 2022 Financial and Operational Results - Yahoo Finance
May 12, 2022 | finance.yahoo.com
MeiraGTx Holdings PLC (MGTX) Reports Q1 Loss, Misses Revenue Estimates
May 12, 2022 | globenewswire.com
MeiraGTx Reports First Quarter 2022 Financial and Operational Results - GlobeNewswire
May 12, 2022 | finance.yahoo.com
MeiraGTx Reports First Quarter 2022 Financial and Operational Results
May 10, 2022 | finance.yahoo.com
Companies Like MeiraGTx Holdings (NASDAQ:MGTX) Are In A Position To Invest In Growth
May 9, 2022 | nasdaq.com
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
May 6, 2022 | finance.yahoo.com
MeiraGTx Presents Clinical Data on Botaretigene Sparoparvovec for the Treatment of X-Linked Retinitis Pigmentosa at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting - Yahoo Finance
May 5, 2022 | nasdaq.com
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
See More Headlines
Receive MGTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter.

MGTX Company Calendar

Last Earnings
11/10/2021
Today
8/18/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MGTX
CUSIP
N/A
CIK
1735438
Web
www.meiragtx.com
Phone
(646) 860-7985
Fax
N/A
Employees
287
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.25
High Stock Price Forecast
$47.00
Low Stock Price Forecast
$18.00
Forecasted Upside/Downside
+205.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.27)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-79,560,000.00
Net Margins
-227.29%
Pretax Margin
-227.29%
Return on Equity
-59.65%
Return on Assets
-34.67%

Debt

Debt-to-Equity Ratio
0.13
Current Ratio
1.55
Quick Ratio
1.55

Sales & Book Value

Annual Sales
$37.70 million
Price / Sales
11.75
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.18 per share
Price / Book
3.12

Miscellaneous

Outstanding Shares
44,710,000
Free Float
38,764,000
Market Cap
$443.08 million
Optionable
Not Optionable
Beta
1.76

Key Executives

  • Dr. Alexandria Forbes (Age 57)
    CEO, Pres & Director
    Comp: $3.05M
  • Mr. Richard Brian Giroux B.A. (Age 48)
    COO & CFO
    Comp: $2.39M
  • Dr. Robert K. Zeldin M.D. (Age 59)
    Chief Medical Officer
    Comp: $1.1M
  • Mr. Robert J. Wollin J.D. (Age 45)
    Gen. Counsel & Sec.
  • Dr. Stuart Naylor Ph.D. (Age 59)
    Chief Devel. Officer
  • Dr. Michel Michaelides M.D.
    Head of Clinical Ophthalmology
  • Ms. Christine Elise Sheehy (Age 54)
    Sr. VP of Global Integration
  • Mr. Joel P. Brooks (Age 63)
    Sr. VP of Fin.
  • Mr. Tim Randall
    Sr. VP of Risk & Internal Controls
  • Dr. Alastair Leighton Ph.D.
    Sr. VP of Manufacturing & Supply Chain

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MGTX Stock - Frequently Asked Questions

Should I buy or sell MeiraGTx stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MGTX shares.
View MGTX analyst ratings or view top-rated stocks.

What is MeiraGTx's stock price forecast for 2022?

2 equities research analysts have issued 1 year price targets for MeiraGTx's stock. Their MGTX share price forecasts range from $18.00 to $47.00. On average, they predict the company's stock price to reach $30.25 in the next year. This suggests a possible upside of 209.0% from the stock's current price.
View analysts price targets for MGTX or view top-rated stocks among Wall Street analysts.

How have MGTX shares performed in 2022?

MeiraGTx's stock was trading at $23.74 at the beginning of 2022. Since then, MGTX shares have decreased by 58.8% and is now trading at $9.79.
View the best growth stocks for 2022 here.

When is MeiraGTx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our MGTX earnings forecast.

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings plc (NASDAQ:MGTX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.08. The business earned $6.95 million during the quarter, compared to analysts' expectations of $5 million. MeiraGTx had a negative net margin of 227.29% and a negative trailing twelve-month return on equity of 59.65%.

What other stocks do shareholders of MeiraGTx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MeiraGTx investors own include AbbVie (ABBV), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Inovio Pharmaceuticals (INO), Pfizer (PFE), VBI Vaccines (VBIV), Novavax (NVAX), Viking Therapeutics (VKTX) and Advanced Micro Devices (AMD).

When did MeiraGTx IPO?

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by many different institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (4.01%), Prosight Management LP (2.21%), Royce & Associates LP (1.46%), State Street Corp (1.11%), UBS Asset Management Americas Inc. (0.65%) and JPMorgan Chase & Co. (0.57%). Insiders that own company stock include Alexandria Forbes, Elizabeth A Cook, Joel S Marcus, Nicole Seligman, Richard Giroux, Robert J Wollin, Robert K Zeldin, Stuart Naylor and Thomas E Shenk.
View institutional ownership trends.

How do I buy shares of MeiraGTx?

Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $9.79.

How much money does MeiraGTx make?

MeiraGTx (NASDAQ:MGTX) has a market capitalization of $437.71 million and generates $37.70 million in revenue each year. The company earns $-79,560,000.00 in net income (profit) each year or ($2.27) on an earnings per share basis.

How many employees does MeiraGTx have?

The company employs 287 workers across the globe.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 14thFloor, NEW YORK NY, 10016. The official website for the company is www.meiragtx.com. The company can be reached via phone at (646) 860-7985 or via email at investors@meiragtx.com.

This page (NASDAQ:MGTX) was last updated on 8/18/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.